PRSS22 and colorectal carcinoma: Our study has identified a cell subcluster that is closely linked to progression, immune dysregulation and prognosis in CRC, and we have also identified PRSS22 as its hub gene that has great potential to become a new immunotherapeutic targets target for CRC.